Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ayala Pharmaceuticals Inc (ADXS)

Ayala Pharmaceuticals Inc (ADXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,226
  • Shares Outstanding, K 10,752
  • Annual Sales, $ 10 K
  • Annual Income, $ -48,070 K
  • 60-Month Beta 1.63
  • Price/Sales 181.96
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ADXS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.02
  • Most Recent Earnings $-2.96 on 04/16/24
  • Next Earnings Date 02/19/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1350 +122.22%
on 05/15/24
0.6650 -54.89%
on 04/29/24
-0.2720 (-47.55%)
since 04/19/24
3-Month
0.1350 +122.22%
on 05/15/24
0.9689 -69.04%
on 03/01/24
-0.6700 (-69.07%)
since 02/21/24
52-Week
0.1350 +122.22%
on 05/15/24
1.9500 -84.62%
on 07/24/23
-0.4200 (-58.33%)
since 05/19/23

Most Recent Stories

More News
Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...

ADXS : 0.3000 (unch)
ADXSD : 3.8500 (+8.45%)
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on...

ADXS : 0.3000 (unch)
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients...

ADXS : 0.3000 (unch)
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the...

ADXS : 0.3000 (unch)
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this...

ADXS : 0.3000 (unch)
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS

Kahn Swick & Foti, LLC and Monteverde & Associates PC announce that, on March 28, 2022, Advaxis, Inc. issued a Supplemental Proxy Statement that includes additional clarifying information about...

ADXS : 0.3000 (unch)
Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update

Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Priced Offering of $5 Million Convertible...

ADXS : 0.3000 (unch)
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update

MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development...

ADXS : 0.3000 (unch)
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development...

ADXS : 0.3000 (unch)
Advaxis Announces Acceptance for Trading on the OTCQX

MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development...

ADXS : 0.3000 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ayala Pharmaceuticals Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. It also involved in developing proprietary Lm-based antigen delivery products for patients suffering...

See More

Key Turning Points

3rd Resistance Point 0.4950
2nd Resistance Point 0.4200
1st Resistance Point 0.3600
Last Price 0.3000
1st Support Level 0.2250
2nd Support Level 0.1500
3rd Support Level 0.0900

See More

52-Week High 1.9500
Fibonacci 61.8% 1.2567
Fibonacci 50% 1.0425
Fibonacci 38.2% 0.8283
Last Price 0.3000
52-Week Low 0.1350

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar